Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues
Brian Godman, Biljana Tubic, Eleonora Allocati, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi , Mainul Haque, Sean MacBride-Stewart, Francis Kalemeera, Amos Massele, Iris Hoxha, Vanda Markovic Pekovic, Guenka Petrova, Konstantin Tachkov, Ott Laius, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuoliené, Patricia Vella Bonanno, Jakub Rutkowski, Ileana Mardare , Jurij Fürst, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Farhana Akter, Hye-Young Kwon, Antony P. Martin, Rita Banzi, Janney Wale, Jolanta Gulbinovic
DOI: 10.7324/JAPS.2022.120306Pages: 055–072
Biosimilar drug lag and evolution in Malaysia: A retrospective analysis of regulatory approvals
Nguyen Thao My Hoang, Omotayo Fatokun, Muhammad Junaid Farrukh
DOI: 10.7324/JAPS.2025.199198Pages: 179-188
_.jpg)